Premium
Hormonal Therapy of Prostatic Carcinoma
Author(s) -
Crawford E. David
Publication year - 1990
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.1990.66.s5.1035
Subject(s) - medicine , prostate cancer , antiandrogen , blockade , orchiectomy , testosterone (patch) , androgen , goserelin , androgen suppression , radiation therapy , oncology , cancer , urology , prostatectomy , prostate , hormone , receptor
Prostate cancer is the most common neoplasm in the American male. More than 50% of patients present with locally advanced or metastatic disease and are not curable with local therapies such as radical prostatectomy or radiation therapy. This cancer is hormonally dependent, and methods that interrupt the hypothalamus‐pituitary‐testicular axis have been used to treat and control the disease effectively. The role of neutralizing the adrenal androgens is controversial. Combined androgen blockade refers to treatment modalities that lower circulating serum testosterone such as bilateral orchiectomy or an LH‐RH agonist and combining it with an antiandrogen. The issue at hand is to review current clinical trials addressing the concept of combined androgen blockade and to determine the feasibility of a meta‐analysis.